Maternal-Fetal Medicine at New Jersey’s First and Only Comprehensive Fetal Diagnostic and Treatment Center: Dr. Karen Russo on Caring for Mothers and Babies Together - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Maternal-Fetal Medicine at New Jersey’s First and Only Comprehensive Fetal Diagnostic and Treatment Center: Dr. Karen Russo on Caring for Mothers and Babies Together

Dr. Karen Russo admits she isn’t overly formal. The down-to-earth approach is part of what defines the first-of-its-kind Hersh Fetal Diagnostic and Treatment Center in New Jersey.

  • February 2, 2026

  • 4 min

Share

Objective:

To highlight the unique approach and philosophy of the Hersh Fetal Diagnostic and Treatment Center in managing high-risk pregnancies.

Approach:
    Key Findings:
    • The Hersh Fetal Center provides a multidisciplinary approach to high-risk pregnancies, improving patient care.
    • Patients benefit from coordinated schedules and a nurse navigator, alleviating the stress of managing multiple appointments.
    • The center's support team, including social workers and genetic counselors, offers essential emotional support to families.
    Interpretation:

    The Hersh Fetal Center's model enhances maternal-fetal care by integrating services and fostering communication, ultimately improving outcomes for mothers and babies.

    Limitations:
    • The article does not provide quantitative data on patient outcomes or satisfaction.
    • Limited information on the specific challenges faced by families in navigating care prior to the center's establishment.
    Conclusion:

    Dr. Russo's work at the Hersh Fetal Center exemplifies a compassionate and comprehensive approach to maternal-fetal medicine, ensuring families do not face difficult journeys alone.

Original Source(s)

Maternal-Fetal Medicine at New Jersey’s First and Only Comprehensive Fetal Diagnostic and Treatment Center: Dr. Karen Russo on Caring for Mothers and Babies Together

  • February 2, 2026

Related Content

CKM staging faces an early vascular test

Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.